WESTBOROUGH, Massachusetts--January 1, 2020--Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that Michael J. McNulty has joined the company as vice president of sales and marketing. McNulty will lead Miach’s commercialization and sales efforts for the Bridge-Enhanced® ACL Repair (BEAR®) Implant, an investigational device designed for anterior cruciate ligament (ACL) repair.
“Mike is a talented commercial leader who is skilled at hiring, developing and motivating his team to consistently deliver exceptional sales performance,” said Martha Shadan, president and CEO, Miach Orthopaedics. “We have worked together in the past to build a successful business based around a totally new orthopaedic treatment, and I look forward to partnering with him to leverage our experience as we begin planning for the launch of the BEAR Implant.”
McNulty brings more than 20 years of global medical device commercial experience at both large and small companies. Most recently, McNulty served as senior director of sales in the Biologics Division at Smith & Nephew following the company’s acquisition of Rotation Medical, where he served as vice president of sales and marketing. Under his commercial leadership, sales of the bioinductive implant for rotator cuff repair outperformed expectations at both Rotation Medical and Smith & Nephew. Previously, McNulty served as vice president of sales for Arstasis, where he was responsible for market development, commercial launch, sales training and sales management. He has also held multiple roles at Cordis, a Johnson & Johnson Company, where he helped launch several disruptive technologies to the market and led sales training and sales management for both the Cardiology and Endovascular divisions. McNulty served as an officer in the Armor Cavalry Branch of the United States Army from 1995-1998. He holds a Bachelor of Arts degree and graduated with honors from Clemson University.
Every year, approximately 400,000 anterior cruciate ligament (ACL) injuries occur in the U.S. Without treatment, the ACL does not heal, resulting in ACL reconstruction surgery being one of the most common orthopaedic procedures in the U.S. Miach Orthopaedics’ new Bridge-Enhanced® ACL Repair (BEAR®) technology is a proprietary bio-engineered bridging scaffold used to facilitate healing of the torn ACL. It is hoped this new technology will restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR II pivotal study completed enrollment, and the BEAR implant is only available in ongoing FDA-approved clinical trials.
Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an ACL injury. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Twitter and LinkedIn.